RU2011146556A - Применение 5-(азаридин-1-ил)-4-гидроксиламино-2нитробензамида в качестве лекарственного средства для борьбы с нежелательным ростом или пролиферацией клеток - Google Patents
Применение 5-(азаридин-1-ил)-4-гидроксиламино-2нитробензамида в качестве лекарственного средства для борьбы с нежелательным ростом или пролиферацией клеток Download PDFInfo
- Publication number
- RU2011146556A RU2011146556A RU2011146556/15A RU2011146556A RU2011146556A RU 2011146556 A RU2011146556 A RU 2011146556A RU 2011146556/15 A RU2011146556/15 A RU 2011146556/15A RU 2011146556 A RU2011146556 A RU 2011146556A RU 2011146556 A RU2011146556 A RU 2011146556A
- Authority
- RU
- Russia
- Prior art keywords
- azaridin
- hydroxylamino
- nitrobenzamide
- solution
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/02—Treatment of flour or dough by adding materials thereto before or during baking by adding inorganic substances
- A21D2/06—Reducing agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B31/00—Reduction in general
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
- C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
- C07D203/14—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Mechanical Engineering (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Abstract
1. Фармацевтическая композиция, содержащая 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамид и фармацевтически примелемый носитель.2. Применение 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамида в производстве лекарственного средства для борьбы с нежелательным ростом или пролиферацией клеток у индивидуума.3. Применение по п.2, при котором нежелательный рост или пролиферация клеток у индивидуума являются доброкачественными и представляют собой бородавку или псориаз, или предраковую гиперплазию.4. Применение по п.4, при котором нежелательный рост или пролиферация клеток у индивидуума являются неопластическими.5. Применение по п.4, при котором нежелательный рост или пролиферация клеток у индивидуума являются опухолевыми.6. Фармацевтическая композиция по п.1, которая представляет собой раствор или суспензию, содержащие 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамид и фармацевтически приемлемый адьювант, разбавитель или носитель.7. Раствор или суспензия, содержащие 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамид и фармацевтически приемлемый адьювант, разбавитель или носитель, и являющиеся распыляемыми.8. Раствор или суспензия по п.7, применяемые для лечения рака мочевого пузыря, цервикального рака, рака яичника или рака головного мозга.9. Раствор или суспензия по п.7, применяемые для лечения рака рта, носовой полости, горла, глотки, гортани, трахеи или легких.10. Механический распылитель, имеющий резервуар, нагруженный раствором или суспензией, содержащими 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамид и фармацевтически приемлемый адьювант, разбавитель или носитель.11. Аэрозольное устройство, содержащее раствор или �
Claims (13)
1. Фармацевтическая композиция, содержащая 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамид и фармацевтически примелемый носитель.
2. Применение 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамида в производстве лекарственного средства для борьбы с нежелательным ростом или пролиферацией клеток у индивидуума.
3. Применение по п.2, при котором нежелательный рост или пролиферация клеток у индивидуума являются доброкачественными и представляют собой бородавку или псориаз, или предраковую гиперплазию.
4. Применение по п.4, при котором нежелательный рост или пролиферация клеток у индивидуума являются неопластическими.
5. Применение по п.4, при котором нежелательный рост или пролиферация клеток у индивидуума являются опухолевыми.
6. Фармацевтическая композиция по п.1, которая представляет собой раствор или суспензию, содержащие 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамид и фармацевтически приемлемый адьювант, разбавитель или носитель.
7. Раствор или суспензия, содержащие 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамид и фармацевтически приемлемый адьювант, разбавитель или носитель, и являющиеся распыляемыми.
8. Раствор или суспензия по п.7, применяемые для лечения рака мочевого пузыря, цервикального рака, рака яичника или рака головного мозга.
9. Раствор или суспензия по п.7, применяемые для лечения рака рта, носовой полости, горла, глотки, гортани, трахеи или легких.
10. Механический распылитель, имеющий резервуар, нагруженный раствором или суспензией, содержащими 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамид и фармацевтически приемлемый адьювант, разбавитель или носитель.
11. Аэрозольное устройство, содержащее раствор или суспензию, содержащие один или более газовых пропелента и 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамид и фармацевтически приемлемый адьювант, разбавитель или носитель.
12. Сухая порошковая аэрозольная композиция, содержащая 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамид.
13. Терапевтическая система, содержащая:
(i) устройство для ингаляции сухого порошка, и, при необходимости, источник препелентного газа;
(ii) одну или более отдельную дозу аэрозольной сухой порошковой композиции, содержащей 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамид.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0526552A GB0526552D0 (en) | 2005-12-29 | 2005-12-29 | New use |
GB0526552.5 | 2005-12-29 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008131054/15A Division RU2445078C2 (ru) | 2005-12-29 | 2006-12-29 | Применение альфа-гидроксикарбонильных соединений в качестве восстанавливающих веществ |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2011146556A true RU2011146556A (ru) | 2013-05-27 |
Family
ID=35841324
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008131054/15A RU2445078C2 (ru) | 2005-12-29 | 2006-12-29 | Применение альфа-гидроксикарбонильных соединений в качестве восстанавливающих веществ |
RU2011146556/15A RU2011146556A (ru) | 2005-12-29 | 2011-11-16 | Применение 5-(азаридин-1-ил)-4-гидроксиламино-2нитробензамида в качестве лекарственного средства для борьбы с нежелательным ростом или пролиферацией клеток |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008131054/15A RU2445078C2 (ru) | 2005-12-29 | 2006-12-29 | Применение альфа-гидроксикарбонильных соединений в качестве восстанавливающих веществ |
Country Status (16)
Country | Link |
---|---|
US (3) | US9029569B2 (ru) |
EP (2) | EP2258430B1 (ru) |
JP (2) | JP5368803B2 (ru) |
KR (1) | KR20080091354A (ru) |
CN (4) | CN101389320B (ru) |
AU (1) | AU2006329678B2 (ru) |
CA (2) | CA2635388C (ru) |
ES (2) | ES2399288T3 (ru) |
GB (1) | GB0526552D0 (ru) |
HK (1) | HK1204269A1 (ru) |
IL (1) | IL192507A0 (ru) |
MX (1) | MX2008008616A (ru) |
NO (1) | NO20082852L (ru) |
NZ (1) | NZ569483A (ru) |
RU (2) | RU2445078C2 (ru) |
WO (1) | WO2007074344A1 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0526552D0 (en) | 2005-12-29 | 2006-02-08 | Morvus Technology Ltd | New use |
WO2009079078A1 (en) | 2007-12-14 | 2009-06-25 | Labogroup S.A.S. | Delivering aerosolizable food products |
AU2009304542A1 (en) * | 2008-10-15 | 2010-04-22 | Xingnong Wang | Use of tetrose to inhibit cancer and to increase cell viability |
US20110216880A1 (en) * | 2010-03-05 | 2011-09-08 | General Electric Company | System and method for molecular breast imaging |
US8691198B2 (en) * | 2010-06-25 | 2014-04-08 | Somogyi Agtech Llc | Environmentally benign plasticizers based on derivatives of acetone |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3208999A (en) | 1964-09-09 | 1965-09-28 | Nat Starch Chem Corp | Preparation of non-inhibited starch amines |
US3658788A (en) * | 1969-06-06 | 1972-04-25 | Salk Inst For Biological Studi | Aminooxazolines and products thereof and processes for synthesizing same |
US3711602A (en) * | 1970-10-30 | 1973-01-16 | Crown Zellerbach Corp | Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso |
JPS52145523A (en) * | 1976-05-28 | 1977-12-03 | Kouki Yagishita | Antiitumor agent |
DE2730720C2 (de) * | 1977-07-07 | 1979-07-12 | Basf Ag, 6700 Ludwigshafen | Verfahren zur Herstellung von praktisch reinem l-Amino-8-nitro-43dihydroxy-anthrachinon |
CA1089763A (en) | 1978-10-30 | 1980-11-18 | Willard J. Johnson | Rodenticide comprising 6-aminonicotinamide and 6- aminonicotinohydroxamic acid |
CS204501B1 (en) | 1978-11-06 | 1981-04-30 | Miroslav Dub | Shaped trap for regulation of the numbers of exoantropous and hemisynantropous rodents classes |
US4375394A (en) * | 1982-03-11 | 1983-03-01 | Eastman Kodak Company | Electrolytic process for the preparation of ethylene glycol and glycerine |
ATE66375T1 (de) * | 1984-10-05 | 1991-09-15 | Bioferon Biochem Substanz | Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung. |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
GB8804068D0 (en) | 1988-02-22 | 1988-03-23 | Roberts J R | Improvements relating to control of neoplastic tissue growth |
CH680180B5 (ru) | 1988-07-29 | 1993-01-15 | Ciba Geigy Ag | |
DE3833194A1 (de) | 1988-09-30 | 1990-04-05 | Basf Ag | Verfahren zum faerben von textilen materialien aus cellulosefasern |
DE4103639A1 (de) | 1991-02-07 | 1992-08-13 | Basf Ag | Verfahren zum faerben von textilen materialien aus cellulosefasern |
AU681337B2 (en) | 1991-10-23 | 1997-08-28 | Cancer Research Campaign Technology Limited | Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form |
GB9412394D0 (en) | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
DE4425436A1 (de) | 1994-07-19 | 1996-01-25 | Basf Ag | Verfahren zur Herstellung von Acyloinen |
GB9415167D0 (en) | 1994-07-27 | 1994-09-14 | Springer Caroline J | Improvements relating to cancer therapy |
US5632782A (en) * | 1994-09-01 | 1997-05-27 | Clariant Finance (Bvi) Ltd. | Exhaust dyeing process for sulphur dyes |
US20040053208A1 (en) | 1995-08-29 | 2004-03-18 | V. I. TECHNOLOGIES, Inc. | Methods to selectively inactivate parasites in biological compositions |
AU1166097A (en) | 1995-12-21 | 1997-07-17 | British Technology Group Limited | Indoloquinone derivatives as bioreductive agents |
JP2001513078A (ja) * | 1996-12-30 | 2001-08-28 | バテル・メモリアル・インスティテュート | 吸入により新生物を治療する製剤とその方法 |
EP0988057B1 (en) | 1997-02-11 | 2003-08-27 | The Victoria University Of Manchester | Bioreductive conjugates for drug targeting |
GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
GB2365338B (en) | 1997-06-14 | 2002-04-03 | Enzacta R & D Ltd | Therapeutic systems |
GB9712370D0 (en) * | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
US6159706A (en) | 1997-12-23 | 2000-12-12 | Newbiotics, Inc. | Application of enzyme prodrugs as anti-infective agents |
AU750381B2 (en) | 1998-05-22 | 2002-07-18 | Shionogi Bioresearch Corp. | Bioreductive cytotoxic agents |
AU768640C (en) | 1998-08-19 | 2005-02-17 | University Of Manchester, The | Drug targeting |
CA2388844A1 (en) * | 1999-11-12 | 2001-05-25 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors |
MXPA02008637A (es) | 2000-03-02 | 2004-09-06 | Ml Lab Plc | Elemento de respuesta a factor de celulas t. |
EE200200710A (et) * | 2000-06-22 | 2004-06-15 | Pfizer Products Inc. | Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks |
DE10049468A1 (de) | 2000-10-06 | 2002-04-11 | Bayer Ag | N-Alkoxyalkyl-substituierte Benzimidazole, ihre Herstellung und ihre Verwendung als Mittel gegen parasitäre Protozoen |
CA2432797C (en) * | 2000-12-18 | 2014-02-04 | David J. Yang | Local regional chemotherapy and radiotherapy using in situ hydrogel |
US20030228285A1 (en) | 2002-05-03 | 2003-12-11 | Mien-Chie Hung | Bipartite T-cell factor (Tcf)-responsive promoter |
GB0223696D0 (en) | 2002-10-14 | 2002-11-20 | Ml Lab Plc | Improved immunotherapy |
GB0313604D0 (en) | 2003-06-12 | 2003-07-16 | Britannia Pharmaceuticals Ltd | Delivery device for powdered medicament |
DE102004009434A1 (de) | 2004-02-24 | 2005-12-15 | Boehringer Ingelheim International Gmbh | Zerstäuber |
FR2871697B1 (fr) | 2004-06-17 | 2007-06-29 | Galderma Sa | Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile |
WO2006003492A2 (en) | 2004-07-02 | 2006-01-12 | Warner-Lambert Company Llc | Compositions and methods for treating pathological infections |
GB0517957D0 (en) | 2005-09-03 | 2005-10-12 | Morvus Technology Ltd | Method of combating infection |
GB0526552D0 (en) | 2005-12-29 | 2006-02-08 | Morvus Technology Ltd | New use |
-
2005
- 2005-12-29 GB GB0526552A patent/GB0526552D0/en not_active Ceased
-
2006
- 2006-12-29 KR KR20087018577A patent/KR20080091354A/ko not_active Application Discontinuation
- 2006-12-29 CN CN200680053566.4A patent/CN101389320B/zh active Active
- 2006-12-29 ES ES06831498T patent/ES2399288T3/es active Active
- 2006-12-29 CN CN201310241391.1A patent/CN103315995B/zh active Active
- 2006-12-29 WO PCT/GB2006/004947 patent/WO2007074344A1/en active Application Filing
- 2006-12-29 MX MX2008008616A patent/MX2008008616A/es active IP Right Grant
- 2006-12-29 CA CA2635388A patent/CA2635388C/en active Active
- 2006-12-29 AU AU2006329678A patent/AU2006329678B2/en active Active
- 2006-12-29 EP EP10075381.3A patent/EP2258430B1/en active Active
- 2006-12-29 US US12/159,363 patent/US9029569B2/en active Active
- 2006-12-29 CN CN201410341330.7A patent/CN104188943B/zh active Active
- 2006-12-29 NZ NZ56948306A patent/NZ569483A/xx not_active IP Right Cessation
- 2006-12-29 JP JP2008548029A patent/JP5368803B2/ja active Active
- 2006-12-29 EP EP06831498A patent/EP1951213B1/en active Active
- 2006-12-29 CA CA2826746A patent/CA2826746C/en active Active
- 2006-12-29 RU RU2008131054/15A patent/RU2445078C2/ru not_active IP Right Cessation
- 2006-12-29 CN CN201710224938.5A patent/CN107080746B/zh active Active
- 2006-12-29 ES ES10075381.3T patent/ES2623857T3/es active Active
-
2008
- 2008-06-27 NO NO20082852A patent/NO20082852L/no not_active Application Discontinuation
- 2008-06-29 IL IL192507A patent/IL192507A0/en unknown
-
2011
- 2011-11-16 RU RU2011146556/15A patent/RU2011146556A/ru not_active Application Discontinuation
-
2013
- 2013-01-30 JP JP2013015431A patent/JP5699170B2/ja active Active
-
2015
- 2015-02-23 US US14/628,980 patent/US9907784B2/en active Active
- 2015-05-20 HK HK15104794.3A patent/HK1204269A1/xx unknown
-
2018
- 2018-01-19 US US15/875,230 patent/US10398676B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2011146556A (ru) | Применение 5-(азаридин-1-ил)-4-гидроксиламино-2нитробензамида в качестве лекарственного средства для борьбы с нежелательным ростом или пролиферацией клеток | |
MX2023001592A (es) | Inhalador de polvo seco. | |
DE69103281D1 (de) | Inhaliergerät. | |
NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
MY172371A (en) | A dry powder inhaler and system for drug delivery | |
EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
BRPI0602430A (pt) | composição medicinal, inalador para composição medicinal, método de tratamento de um mamìfero, recipiente do tipo capaz de conter a pressão de vapor de um propelente contido em seu interior e adicionalmente contendo uma composição medicinal adequada para administração a um mamìfero, método de produzir uma formulação aerossol adequada para transferência aos pulmões de um mamìfero por inalação | |
MX2013003621A (es) | Inhalador. | |
AU2003217965A1 (en) | Pulmonary dosing system and method | |
RU2015129062A (ru) | Соединения 3, 5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида | |
RS49760B (sr) | Inhalator za suvi prah | |
NZ585857A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
TW200607538A (en) | Medicament inhaler device | |
RU99118588A (ru) | Новый препарат для ингаляции, имеющий насыпную объемную плотность от 0,28 до 0,38 г/мл, содержащий формотерол | |
MX2022015554A (es) | Moduladores de molecula peque?a de interleucina 17 (il-17). | |
NO20073909L (no) | Forstover-formulering | |
WO2015014209A1 (zh) | 稳定渗透压的丙酮酸药物组成及其在健康人和肺病病人中的排毒作用 | |
EP2253312A3 (de) | Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von inhalierbaren Arzneimittel zur Prophylaxe und Behandlung pulmonaler und kardiovaskulärer Erkrankungen, sowie eine Osmolyte als Wirkstoffbestandteil enthaltende Inhalationsvorrichtung | |
BR112019005080A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para aumentar o tempo de estabilização de uma composição farmacêutica, para melhorar o desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica. | |
JP6630115B2 (ja) | 摘出手術後の体重減少を軽減するための医薬組成物 | |
RU2009141168A (ru) | Способы и композиции, содержащие дезвенлафаксин или дулоксетин, для лечения расстройств дыхания во время сна | |
RU2393839C2 (ru) | Устройство звукового массажа легких с ингаляционной терапией | |
RU2013118026A (ru) | Карбонатные производные для лечения кашля | |
US20220347399A1 (en) | Systems and methods of using an ultrasonic fogger to distribute an antiseptic solution | |
CR10261A (es) | Formulaciones novedosas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20141117 |